Search Results for “research” – Page 45 – media

Chinese scientists release transcriptome map of single-cell space in the cerebellar cortex across species

The cerebellum plays a crucial role in motor and cognitive functions, with region specific functional connections between its cortex and various sensory motor and associative regions of the neocortex. However, compared to the cerebral cortex, the various regions of the cerebellar cortex have relatively uniform cellular structures and typical local circuits, which makes the complexity of how cellular tissue supports cerebellar connections and functions an important issue. Figure 1: Composition of neurons in the cerebellar cortex (Image reference from: https://vanat.ahc.umn.edu/neurLab6/Circuits.html ） In recent years, the development of single-cell omics has driven multiple studies on the composition of cerebellar cells, but previous research on the molecular and functional diversity of cerebellar cortical cells has mainly been based on the mouse cerebellum. The cerebellum of primates has significantly expanded during evolution, with an increase in the number of neurons and more complex cognitive functions. Therefore, determining the existence of primate specific cell ...
- Source: drugdu
- 96
- September 29, 2024
Actively Exploring New Paths for Investment and Mergers, Potential New Drug Commercialization is Imminent

Recently, Sanyuan Gene, a company listed on the Beijing Stock Exchange, stated in discussions with investors that it will adhere to the principle of “prudent research and steady advancement.” The company aims to explore pathways for external investment and mergers centered around its main business direction. It plans to fully utilize various tools and platforms within the capital market to seek high-quality investment or merger targets that can synergistically develop across research, production, and sales, with the goal of achieving higher quality development in both serious medicine and therapeutic medicine markets. In the pharmaceutical sector, the development of innovative drug companies is a critical component of new productive forces and is receiving significant attention from capital markets. As a national-level specialized “little giant” enterprise, Sanyuan Gene has been deeply involved in the biopharmaceutical field for 32 years. Since its listing on the Beijing Stock Exchange, the company has actively responded ...
- Source: drugdu
- 105
- September 29, 2024
Pfizer and Shanghai Pharmaceuticals Reach Strategic Cooperation to Create High-Quality Preventive Immunization Services

On September 26, Pfizer Investment Co., Ltd. (referred to as Pfizer) and Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as Shanghai Pharmaceuticals) signed a strategic cooperation framework agreement. The two parties will focus on the vaccine field, engaging in long-term collaboration in product promotion, the introduction of innovative products, and policy research. Leveraging their respective strengths, they will explore strategies to deepen and enhance their partnership in the commercial promotion of vaccine products and accelerate the introduction of innovative products, along with thorough cooperation in policy research and capacity training. This effort aims to support the robust development of China’s public health services and disease control efforts, ultimately aiding disease prevention and health improvement across all stages of life. Jean-Christophe Pointeau, President of Pfizer China, stated: “The collaboration between Pfizer and Shanghai Pharmaceuticals will harness both parties’ strengths to empower the promotion and dissemination of innovative vaccines scientifically, allowing internationally ...
- Source: drugdu
- 80
- September 29, 2024
Domestic ultrasonic scalpel industry enters “life and death situation”

In a recent survey of front-line practitioners in the ultrasonic scalpel industry, the most common answer was that the industry is going through a period of pain. The general consensus is that domestic brands will undergo a major reshuffle this year and next. Zhang Tao, founder of Ansukang, believes that from the first domestic ultrasonic scalpel certification in 2013 to 2023, it took about ten years for domestic brands to develop from scratch. Next, domestic brands are moving towards a new stage from existence to excellence. Half sea water, half fireworks. Judging from the data on paper, the domestic ultrasonic scalpel market will see rapid growth in sales in 2023. According to data recently released by a market research institution, domestic ultrasonic scalpels (excluding the blade) are increasing rapidly and have reversed the import monopoly. But when Artery.com used data to explore the drivers of growth from front-line personnel in ...
- Source: drugdu
- 86
- September 29, 2024
The audit storm continues, strictly checking the loopholes in hospital accounts

Recently, the National Audit Office released the audit dynamics “holding a video conference on audit rectification work, conducting public health construction project audits…” It mentioned that the Audit Bureau of Wuhan City, Hubei Province, conducted an audit of public health construction projects at the municipal level. The Audit Bureau of Wuhan City examines whether the construction projects comply with relevant plans, industrial and industry policies, whether the funds are raised in place, whether the project approval procedures are complete, and whether the projects are promoted on schedule, to promote the implementation of public health projects. Pay attention to the construction of major epidemic treatment bases at the municipal level, review the construction of negative pressure wards and negative pressure operating rooms, whether the infectious disease beds, normal beds, and peacetime and wartime beds meet the planning requirements, the designated hospital hemodialysis machine reserves meet the standards, whether the medical supplies ...
- Source: drugdu
- 67
- September 29, 2024
Implantation of mesenchymal stem cells significantly improves motor function in patients with brain injury

Traumatic brain injury (TBI) is a heterogeneous disease characterized by brain damage and functional impairment caused by external forces. Under the influence of multiple mechanisms, the disability and mortality rates of TBI patients are relatively high, which imposes a heavy burden on families and society. The clinical treatment of TBI mainly involves surgical intervention and symptomatic treatment to alleviate cerebral hypoxia, cerebral edema, and metabolic disorders. In recent years, stem cells have gradually become one of the research hotspots for TBI treatment.A research team from the United States and Japan published a clinical observation report titled Mesenchymal Stromal Cell Implants for Chronic Motor Defects After Traumatic Brain Injury in the Neurology journal on September 4, 2024. The researchers found that implanting mesenchymal stem cell (SB623) cells can help TBI patients restore motor function and daily life skills.Traumatic brain injury (TBI) is the leading cause of death and disability in trauma ...
- Source: drugdu
- 92
- September 28, 2024
Johnson&Johnson’s application for marketing of bevacizumab injection (subcutaneous injection) has been accepted

Public information shows that this is a subcutaneous administration fixed combination of the EGFR/MET bispecific antibody amivantamab developed by Johnson&Johnson and recombinant human hyaluronidase. In June of this year, Johnson&Johnson submitted a biopharmaceutical approval application for subcutaneous injection of bevacizumab to the US FDA, for all indications of approved or submitted intravenous bevacizumab preparations, covering different types of non-small cell lung cancer (NSCLC). According to Johnson&Johnson’s previous press release, patients were able to complete the injection of the subcutaneous formulation within 5 minutes. Evantomab is a humanized EGFR/MET bispecific antibody. It has multiple anti-cancer mechanisms, not only blocking EGFR and MET mediated signaling, but also guiding immune cells to target tumors carrying activating and drug-resistant EGFR/MET mutations and amplifications. The intravenous formulation of this product was first granted accelerated approval by the FDA in May 2021, and has since been approved for multiple indications, including:  Adult patients with locally ...
- Source: drugdu
- 73
- September 28, 2024
CT angiography image assisted detection software for intracranial aneurysms approved for market launch

On September 25th, the National Medical Products Administration announced that it has recently approved the registration application for the innovative product “CT angiography image assisted detection software for intracranial aneurysms” of Shanghai Lianying Intelligent Medical Technology Co., Ltd. (hereinafter referred to as “Lianying Intelligent”). Effective improvement, innovative products begin to emerge Lianying Intelligence is an artificial intelligence company under Lianying Group, established in Shanghai at the end of 2017. It is an important strategic layout of Lianying Group in the field of artificial intelligence. Relying on the high-performance software and hardware technology platform and resource advantages of Lianying Group, Lianying Intelligence has become a medical AI enterprise that can provide multi scenario, multi disease, full process, and integrated intelligent solutions. It empowers clinical, scientific research, and equipment with AI, covering multiple AI application scenarios such as hospital level management, medical innovation ecology, workflow optimization, precision diagnosis and treatment, and personal ...
- Source: drugdu
- 74
- September 28, 2024
Johnson & Johnson closes two business units

On September 25, according to foreign media Endpoints, Johnson & Johnson is closing the cardiovascular and metabolic drug unit of its pharmaceutical division. This is the second large-scale reorganization since Johnson & Johnson closed its infectious disease and vaccine units. Johnson & Johnson has gradually downplayed cardiopulmonary and metabolic work since last year. Under the change, Johnson & Johnson has narrowed its research and development focus to three therapeutic areas: oncology, immunology and neuroscience. This reorganization mainly affects the commercialization work of the cardiovascular department (sales, marketing and medical affairs teams), not research and development. At present, the cardiovascular department of Johnson & Johnson’s medical device department has not been affected, and its acquisitions are still ongoing. The core product of Johnson & Johnson’s cardiovascular and metabolic drug department is Xarelto (rivaroxaban), which was once one of the world’s best-selling anticoagulants and was jointly developed by Johnson & Johnson and ...
- Source: drugdu
- 71
- September 28, 2024
Brief Bioinform | Li Shiliang/Li Honglin team develops AI method GR pKa value prediction for small molecules based on retention mechanism

Zhiyao Bang The following article is from DeDrug, authored by Li’s Lab On August 22, 2024, the team of Professor Li Shiliang/Li Honglin from East China University of Science and Technology/East China Normal University published a research paper titled “GR pKa: A message feeding neural network with retention mechanism for pKa prediction” in the journal Briefing in Bioinformatics. This paper introduces an innovative deep learning model GR pKa for predicting the pKa values of small chemical molecules. This model combines multiple fidelity learning, quantum chemistry features, and retention mechanisms to achieve rapid and accurate prediction of pKa values of small chemical molecules, providing a powerful new tool for research in the fields of chemistry and pharmacy. Research background In the process of drug discovery and design, the acid-base dissociation constant (pKa) of molecules has a significant impact on the characteristics (absorption, distribution, metabolism, excretion, and toxicity) and biological activity of ...
- Source: drugdu
- 81
- September 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.